Outcome | Kobeni | Timbedra |
---|---|---|
Number of enrolled patients | 65 | 65 |
Exclusion after enrollment (before PCR correction), n | 7 | 2 |
Lost-to-follow-up, n | 0 | 8 |
Per protocol population (before PCR correction), n | 58 | 55 |
PCR-uncorrected outcome | ||
Early treatment failure, n (%) | 0 | 0 |
Late clinical failure (LCF), n (%) | 2 (3.4) | 1 (1.8) |
Late parasitological failure, n (%) | 0 | 0 |
Adequate clinical and parasitological response, n (%) | 56 (96.6) | 54 (98.2) |
Per protocol population after PCR correction, n* | 57 | 55 |
PCR-corrected outcome | ||
Early treatment failure, n (%) | 0 | 0 |
Late clinical failure (LCF) due to recrudescence, n (%) | 1 (1.8) | 1 (1.8) |
Late parasitological failure, n (%) | 0 | 0 |
Adequate clinical and parasitological response, n (%) | 56 (98.2) | 54 (98.2) |
Patients with fever on day 1, n (%) | 13 (22.4) | 7 (12.7) |
Patients with fever on day 2, n (%) | 2 (3.4) | 0 |
Patients with fever on day 3, n (%) | 0 | 0 |
Patients with parasitaemia on day 2, n (%) | 46 (79.3) | 25 (45.5) |
Patients with parasitaemia on day 3, n (%) | 0 | 0 |